Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
Li-Tong Yao, Mo-Zhi Wang, Meng-Shen Wang, Xue-Ting Yu, Jing-Yi Guo, Tie Sun, Xin-Yan Li, Ying-Ying Xu, Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Yao LT and Wang MZ contributed equally to the writing and critical revision of this manuscript; Wang MS, Yu XT, and Guo JY collected and analyzed the relevant literature; Sun T and Li XY contributed to paper revision and editing; Xu YY is the corresponding author and responsible for the conception, funding, and finalization.
Supported by the National Natural Science Foundation of China, No. 81773083.
Conflict-of-interest statement: The authors have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ying-Ying Xu, PhD, Professor, Department of Breast Surgery, the First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Shenyang 110001, Liaoning Province, China. email@example.com
Telephone: +86-24-83282741 Fax: +86-24-22703578
Received: April 8, 2019
Peer-review started: April 8, 2019
First decision: May 31, 2019
Revised: June 21, 2019
Accepted: July 3, 2019
Article in press: July 3, 2019
Published online: August 6, 2019